Onward Medical NV 2024 AR2
The report highlights ONWARD Medical's milestone year in 2024, marked by the US FDA De Novo authorization and first commercial sales of its ARCEX System for upper limb rehabilitation. The company expanded its intellectual property portfolio to over 290 issued patents and secured EUR 70 million in equity financing, including a strategic investment from Ottobock. Additionally, ONWARD advanced its implantable ARCIM and brain-computer interface (ARCBCI) platforms, receiving its tenth FDA Breakthrough Device Designation. The company was also awarded a silver medal by EcoVadis, placing it in the top 15% of assessed companies for sustainability practices.
Company: Onward Medical NV
Sector: Manufacturing
Country: Netherlands
Year: 2024
Type: AR2
Pages: 175
Back to company
Onward Medical NV
Annual Report
The report highlights ONWARD Medical's milestone year in 2024, marked by the US FDA De Novo authorization and first commercial sales of its ARCEX System for upper limb rehabilitation. The company expanded its intellectual property portfolio to over 290 issued patents and secured EUR 70 million in equity financing, including a strategic investment from Ottobock. Additionally, ONWARD advanced its implantable ARCIM and brain-computer interface (ARCBCI) platforms, receiving its tenth FDA Breakthrough Device Designation. The company was also awarded a silver medal by EcoVadis, placing it in the top 15% of assessed companies for sustainability practices.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees